Normal cardiac function relies on the tight coupling of functionally-related ion channels and transporters in the sarcolemma (plasma membrane and transverse-tubule network, TTs) with calcium-release channels (ryanodine receptors, type 2, RyR2) in the sarcoplasmic reticulum (SR), the intracellular Ca 2+ storage organelle (reviewed in [1]). Cardiac excitation-contraction (EC) coupling is initiated by membrane depolarization during the action potential (AP) that activates voltage-gated L-type Ca 2+ channels (LTCC) in the sarcolemma. The small increase in local [Ca 2+ ] i due to the Ca 2+ flux through the plasma membrane Ca 2+ channels is detected by nearby (15 nm) clusters of RyR2s in the junctional SR (jSR) to produce Ca 2+ sparks. This amplification system (termed "Ca 2+ -induced Ca 2+ release" or CICR) operates at high gain with great stability and is referred to as "local control" because there is a high [Ca 2+ ] i only locally between the LTCC and the jSR (in small space between them called the "subspace") [2][3][4]. The synchronization of Ca 2+ sparks by the AP produces the cell-wide [Ca 2+ ] i transient that activates contraction. Instability in cardiac Ca 2+ management may be due to altered RyR sensitivity ("RyR2 tuning" -see [2,5]), altered spatial organization of local Ca 2+ release sites, or mutations and variants of the RyR2 protein (as those found in specific diseases such as catecholaminergic polymorphic ventricular tachycardia). These changes in cardiac Ca 2+ signaling may result in defects in myocyte electrical activity and multiple human cardiac disease phenotypes, including arrhythmia, myopathy, and heart failure [6].While RyR2 Ca 2+ release channels have received significant attention by molecular cardiologists, in the past five years the role of a second pathway for internal Ca 2+ -release has largely been ignored. Specifically, the cellular role(s) for inositol 1,4,5-trisphosphate receptors (IP 3 R) have remained elusive. However, there is great and growing interest in cardiac IP 3 signaling due to the known importance of several IP 3 -inducing agonists (e.g. angiotensin II, endothelin, and norepinephrine) in hypertrophy and heart failure [7][8][9][10][11][12][13][14][15].While agonist-induced IP 3 -dependent Ca 2+ release is readily observed in most tissues, the role of IP 3 Rs in cardiac tissue is less clear. The subcellular localization of IP 3 Rs in cardiac myocytes has received increasing attention as the field attempts to define the function of these channels. In ventricular myocytes, immunofluorescence studies show that IP 3 Rs are found at the Z-lines, in the perinuclear region and in the nuclear membrane [7,16,17]. Moreover, IP 3 Rs are found